Differential diagnosis of bone marrow failure syndromes guided by machine learning.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
27 04 2023
27 04 2023
Historique:
accepted:
09
12
2022
received:
22
06
2022
pmc-release:
27
04
2024
medline:
1
5
2023
pubmed:
22
12
2022
entrez:
21
12
2022
Statut:
ppublish
Résumé
The choice to postpone treatment while awaiting genetic testing can result in significant delay in definitive therapies in patients with severe pancytopenia. Conversely, the misdiagnosis of inherited bone marrow failure (BMF) can expose patients to ineffectual and expensive therapies, toxic transplant conditioning regimens, and inappropriate use of an affected family member as a stem cell donor. To predict the likelihood of patients having acquired or inherited BMF, we developed a 2-step data-driven machine-learning model using 25 clinical and laboratory variables typically recorded at the initial clinical encounter. For model development, patients were labeled as having acquired or inherited BMF depending on their genomic data. Data sets were unbiasedly clustered, and an ensemble model was trained with cases from the largest cluster of a training cohort (n = 359) and validated with an independent cohort (n = 127). Cluster A, the largest group, was mostly immune or inherited aplastic anemia, whereas cluster B comprised underrepresented BMF phenotypes and was not included in the next step of data modeling because of a small sample size. The ensemble cluster A-specific model was accurate (89%) to predict BMF etiology, correctly predicting inherited and likely immune BMF in 79% and 92% of cases, respectively. Our model represents a practical guide for BMF diagnosis and highlights the importance of clinical and laboratory variables in the initial evaluation, particularly telomere length. Our tool can be potentially used by general hematologists and health care providers not specialized in BMF, and in under-resourced centers, to prioritize patients for genetic testing or for expeditious treatment.
Identifiants
pubmed: 36542832
pii: S0006-4971(22)08447-6
doi: 10.1182/blood.2022017518
pmc: PMC10163315
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2100-2113Commentaires et corrections
Type : CommentIn
Références
N Engl J Med. 2019 Apr 4;380(14):1347-1358
pubmed: 30943338
PLoS One. 2011;6(9):e24383
pubmed: 21931702
PLoS One. 2014 Nov 19;9(11):e113747
pubmed: 25409313
Blood. 2020 Nov 12;136(20):2249-2262
pubmed: 32961553
Blood Adv. 2021 Aug 24;5(16):3216-3226
pubmed: 34427585
Sci Rep. 2018 Jan 11;8(1):411
pubmed: 29323142
J Med Genet. 2015 Sep;52(9):575-84
pubmed: 26136524
Blood. 2014 Oct 30;124(18):2775-83
pubmed: 25237198
BMC Med Res Methodol. 2014 Dec 22;14:137
pubmed: 25532820
NPJ Digit Med. 2018 May 8;1:18
pubmed: 31304302
Nature. 2018 Jul;559(7714):400-404
pubmed: 29988082
N Engl J Med. 2009 Dec 10;361(24):2353-65
pubmed: 20007561
J Am Acad Dermatol. 2020 Dec;83(6):1647-1653
pubmed: 31678339
Haematologica. 2015 Jan;100(1):42-8
pubmed: 25239263
Br J Haematol. 2017 May;177(4):526-542
pubmed: 28211564
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Genet Med. 2017 Oct;19(10):1105-1117
pubmed: 28492532
Br J Haematol. 2021 Mar;192(5):932-941
pubmed: 33506990
Eur J Haematol. 2014 Jun;92(6):467-70
pubmed: 24612308
Lancet Haematol. 2020 Jul;7(7):e541-e550
pubmed: 32589980
Nat Rev Genet. 2015 Jun;16(6):321-32
pubmed: 25948244
N Engl J Med. 2017 Apr 20;376(16):1540-1550
pubmed: 28423296
Br J Haematol. 2021 Jan;192(2):239-250
pubmed: 32602593
N Engl J Med. 2018 Oct 25;379(17):1643-1656
pubmed: 30354958
Blood. 2018 Feb 15;131(7):717-732
pubmed: 29146883
N Engl J Med. 2018 Oct 11;379(15):1416-1430
pubmed: 30304655